Ato

CLL/SLL

Ascentage Pharma Group Inc.Phase 3Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 89/ 100

Competitive context

11 Active assets in the CLL/SLL cohort.

Asset / Sponsor	Phase	Rating
Apg-2575 Henan Cancer Hospital	Phase 3	BBB
Orelabrutinib The First Affiliated Hospital with Nanjing Medical University	Phase 3	BB
Epcoritamab City of Hope Medical Center	Phase 2	BB
Vesanoid Ascentage Pharma Group Inc.	Phase 3	BB
lp-168 Zulfa Omer	Phase 2	B

View all 11 →

Same molecule, other indications

Ato is also rated in:

Acute Promyelocytic Leukemia (APL)Dormant

B

Indicative ·

57 / 100

Mantle Cell Lymphoma (MCL)Dormant

CCC

Indicative ·

53 / 100

Myeloid MalignancyDormant

CC

Indicative ·

47 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.